Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Are dopamine receptor agonists neuroprotective in Parkinson's disease?

Le WD, Jankovic J.

Drugs Aging. 2001;18(6):389-96. Review.

PMID:
11419913
2.

Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease.

Radad K, Gille G, Rausch WD.

Pharmacol Rep. 2005 Nov-Dec;57(6):701-12. Review.

3.

Clinical pharmacology of dopamine agonists in Parkinson's disease.

Lange KW.

Drugs Aging. 1998 Nov;13(5):381-9. Review.

PMID:
9829165
4.

Dopamine agonists.

Factor SA.

Med Clin North Am. 1999 Mar;83(2):415-43, vi-vii. Review.

PMID:
10093586
5.

[Use of dopamine agonists in the treatment of Parkinson's disease].

Gekht AB.

Zh Nevrol Psikhiatr Im S S Korsakova. 2002;102(9):54-8. Review. Russian. No abstract available.

PMID:
12378886
6.

Ropinirole and pramipexole, the new agonists.

Hobson DE, Pourcher E, Martin WR.

Can J Neurol Sci. 1999 Aug;26 Suppl 2:S27-33. Review.

PMID:
10451757
7.

[Neuroprotective effect of dopamine agonists].

Szczudlik A, RudziƄska M.

Neurol Neurochir Pol. 2007 Mar-Apr;41(2 Suppl 1):S22-8. Review. Polish.

PMID:
17941455
8.

Do dopamine agonists provide neuroprotection?

Yamamoto M.

Neurology. 1998 Aug;51(2 Suppl 2):S10-2. Review.

PMID:
9711974
9.

Rationale for dopamine agonist use as monotherapy in Parkinson's disease.

Schwarz J.

Curr Opin Neurol. 2003 Dec;16 Suppl 1:S27-33. Review. Erratum in: Curr Opin Neurol. 2004 Oct;17(5):2 p following 639.

PMID:
15180135
10.

Dopamine agonist monotherapy in Parkinson's disease.

Clarke CE, Guttman M.

Lancet. 2002 Nov 30;360(9347):1767-9. Review.

PMID:
12480442
11.

Do dopamine agonists or levodopa modify Parkinson's disease progression?

Marek K, Jennings D, Seibyl J.

Eur J Neurol. 2002 Nov;9 Suppl 3:15-22. Review.

PMID:
12464117
12.

Treatment of Parkinson's disease should begin with a dopamine agonist.

Montastruc JL, Rascol O, Senard JM.

Mov Disord. 1999 Sep;14(5):725-30. Review.

PMID:
10495032
13.

Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.

Dooley M, Markham A.

Drugs Aging. 1998 Jun;12(6):495-514. Review.

PMID:
9638397
14.

Neuroprotection in idiopathic Parkinson's disease.

Reichmann H.

J Neurol. 2002 Oct;249 Suppl 3:III/21-3. Review.

PMID:
12522567
15.

Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials.

Kulisevsky J, Pagonabarraga J.

Drug Saf. 2010 Feb 1;33(2):147-61. doi: 10.2165/11319860-000000000-00000. Review.

PMID:
20082541
16.

Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease.

Bennett JP Jr, Piercey MF.

J Neurol Sci. 1999 Feb 1;163(1):25-31. Review.

PMID:
10223406
17.

Slowing Parkinson's disease progression: recent dopamine agonist trials.

Pan T, Le W, Jankovic J.

Neurology. 2004 Jan 27;62(2):343; author reply 343-4. No abstract available.

PMID:
14750218
18.

New pharmacotherapy for Parkinson's disease.

Gottwald MD, Bainbridge JL, Dowling GA, Aminoff MJ, Alldredge BK.

Ann Pharmacother. 1997 Oct;31(10):1205-17. Review.

PMID:
9337447
19.

[The role of dopaminagonists in the treatment of Parkinson's disease].

Ransmayr G.

Praxis (Bern 1994). 2005 Oct 19;94(42):1633-8. German.

PMID:
16277084
20.

[Pharmacological profiles and clinical effects of antiparkinsonian agent, pramipexole].

Kohno Y, Takeuchi S.

Nihon Yakurigaku Zasshi. 2004 Jun;123(6):429-40. Review. Japanese.

PMID:
15170083

Supplemental Content

Support Center